Zeng X - Search Results

1

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer.

Wu M, Qin S, Wang L, Tan C, Peng Y, Zeng X, Luo X, Yi L, Wan X. Wu M, et al. Among authors: zeng x. Front Pharmacol. 2022 May 30;13:881787. doi: 10.3389/fphar.2022.881787. eCollection 2022. Front Pharmacol. 2022. PMID: 35712723 Free PMC article.

2

The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

Zeng X, Karnon J, Wang S, Wu B, Wan X, Peng L. Zeng X, et al. PLoS One. 2012;7(10):e48323. doi: 10.1371/journal.pone.0048323. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23118985 Free PMC article.

3

Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.

Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z. Zeng X, et al. Clin Ther. 2013 Jan;35(1):54-65. doi: 10.1016/j.clinthera.2012.12.013. Clin Ther. 2013. PMID: 23328269

4

A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.

Wang S, Peng L, Li J, Zeng X, Ouyang L, Tan C, Lu Q. Wang S, et al. Among authors: zeng x. PLoS One. 2013;8(3):e55917. doi: 10.1371/journal.pone.0055917. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520448 Free PMC article. Clinical Trial.

5

Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.

Tan C, Peng L, Zeng X, Li J, Wan X, Chen G, Yi L, Luo X, Zhao Z. Tan C, et al. Among authors: zeng x. PLoS One. 2013 Dec 10;8(12):e83396. doi: 10.1371/journal.pone.0083396. eCollection 2013. PLoS One. 2013. PMID: 24340099 Free PMC article.

6

Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.

Zeng X, Li J, Peng L, Wang Y, Tan C, Chen G, Wan X, Lu Q, Yi L. Zeng X, et al. PLoS One. 2014 Feb 20;9(2):e88881. doi: 10.1371/journal.pone.0088881. eCollection 2014. PLoS One. 2014. PMID: 24586426 Free PMC article.

7

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.

Peng J, Tan C, Zeng X, Liu S. Peng J, et al. Among authors: zeng x. PLoS One. 2018 Jun 28;13(6):e0199553. doi: 10.1371/journal.pone.0199553. eCollection 2018. PLoS One. 2018. PMID: 29953476 Free PMC article. Clinical Trial.

8

Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.

Wan X, Zhang Y, Ma J, Tan C, Zeng X, Peng L. Wan X, et al. Among authors: zeng x. Breast. 2019 Feb;43:1-6. doi: 10.1016/j.breast.2018.10.004. Epub 2018 Oct 16. Breast. 2019. PMID: 30342258

9

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.

Wan X, Zhang Y, Tan C, Zeng X, Peng L. Wan X, et al. Among authors: zeng x. JAMA Oncol. 2019 Apr 1;5(4):491-496. doi: 10.1001/jamaoncol.2018.7086. JAMA Oncol. 2019. PMID: 30789633 Free PMC article. Clinical Trial.

10

Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR⁺/HER2^- Metastatic Breast Cancer From the US and Chinese Perspectives.

Zhang Y, Zeng X, Deng H, Ma F, Peng Y, Yi L, Tan C, Peng L. Zhang Y, et al. Among authors: zeng x. Clin Ther. 2019 Jun;41(6):1175-1185. doi: 10.1016/j.clinthera.2019.04.033. Epub 2019 May 17. Clin Ther. 2019. PMID: 31104762

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,418 results

Search Page

Filters